Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
APLLTD
Mr. Chirayu Ramanbhai Amin · Vadodara, India · 17,244 employees
₹811.95
▼-0.84%APLLTD's healthcare focus and stable financials have drawn institutional investors, but its high debt levels and modest revenue growth require closer scrutiny.
Exchange
NSI
Currency
INR
Day range
₹802.60 – ₹818.25
52-week range
₹635.80 – ₹1,026.20
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis50% confidence
APLLTD appears fairly valued given its 23.67 P/E ratio and trading in the upper third of its 1-year range, suggesting a cautious approach may be warranted.
20.9% below the 1-year high · trend up
Hedge-fund memo
Today
APLLTD fell 0.84% today, closing at 811.95 INR, as the market reacted to sector dynamics.
This week
It has been range-bound, trading between 802.6 and 818.25 INR, within the established 52-week range.
This month
—
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
4 headlines · 3 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 3 of 4 recent quarters (EPS actual vs. consensus).
11.5694 vs 8.9575
29.16% surprise
8.5142 vs 9.14
-6.85% surprise
9.4 vs 8.69667
8.09% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| APLLTD | 157.79B | 23.37 | 12.36% | 7.39% | 4.40% |
| ALKEM | 695.45B | 30.25 | 17.56% | 11.42% | 14.60% |
| AJANTPHARM | 429.33B | 40.63 | 25.39% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High debt levels
Mitigation: Monitors debt repayment plans and cash flows
Business intelligence
Competitive moat
APLLTD's diversified product portfolio, extensive research and development capabilities, and established relationships with suppliers and customers create a strong competitive moat in the healthcare industry.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Revenue and profitability guidance
Thesis builder
Bull case
APLLTD's diversified product portfolio and growing market share could drive revenue growth and expansion.
Base case
Steady financials and moderate revenue growth may not attract significant price appreciation, but the business remains solid.
Bear case
APLLTD's high debt levels and modest revenue growth may limit its financial flexibility and make it vulnerable to market fluctuations.
Time horizon
6-12 months
Est. CAGR
5-8%
Entry (qual.)
Look for signs of increasing revenue growth and decreasing debt levels.
Exit (qual.)
Sell if there's a significant increase in debt levels or revenue growth slows down.
Overall conviction 50%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how APLLTD fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain APLLTD for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Closely monitor the company's debt repayment plan and revenue growth trajectory.
Passionate In Marketing·1d ago·FDA approval expands market
TradingView·2d ago·FDA approval for multiple strengths
TradingView·2d ago·Revenue breakdown neutral
simplywall.st·5d ago·Dividend payment positive
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
7.85 vs 7.82667
0.30% surprise
| 23.19% |
| 21.50% |
| IPCALAB | 446.21B | 39.18 | 13.22% | 18.48% | 6.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹802.60
Resistance (day/52w high)
₹818.25
Volume
81,696
Trend
up
RSI (14)
49
MACD
bearish
MA cross
death
50-day MA
₹782.79
200-day MA
₹794.12
vs 200-DMA
2.2%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.